tailieunhanh - Báo cáo y học: "Advances in immunomodulating therapy of HBV infection"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: Advances in immunomodulating therapy of HBV infection. | Int. J. Med. Sci. 2005 2 1 24 Review Received Accepted PubliShed Abstract Key words Author biography Corresponding address International Journal of Medical Sciences ISSN 1449-1907 2005 2 1 24-29 2005 Ivyspring International Publisher. All rights reserved Advances in immunomodulating therapy of HBV infection Chee-Kin Hui 1 George KK Lau 2 1. MRC Cancer Cell Unit University of Cambridge Cambridge UK. 2. Department of Medicine University of Hong Kong Hong Kong Patients with chronic hepatitis B virus HBV infection have a higher risk of developing liver cirrhosis and hepatocellular carcinoma. Interferon-a lamivudine and adefovir dipivoxil are the three approved treatment for chronic HBV infection and offers the only means of preventing the development of these complications. However the efficacy of these agents in terms of loss of Hepatitis B e antigen with or without seroconversion to Hepatitis B e antibody normalization of serum alanine transaminase levels loss of serum HBV DNA and improvement in liver histology can only be achieved in 20-30 of those treated. Long-term treatment with either lamivudine or adefovir dipivoxil can result in the development of drug resistant mutants leading to an increased length of treatment with additional nucleoside analogues. These limitations of the current antiviral therapies underline the need for alternative therapies. Specific and nonspecific immunotherapeutic strategies to restore effective virus-specific T cell responses in those with chronic HBV infection offers an interesting alternative approach. These immunotherapeutic therapies include the adoptive transfer of HBV immunity pegylated interferon and therapeutic vaccine therapies. immunomodulating therapy HBV infection George KK Lau MD is an Assistant Dean of the Faculty of Medicine The University of Hong Kong. His research interests include hepatitis B infection in immunosuppressed patients design of immune-related and .